Efficacy of Clostridium butyricum preparation concomitantly with Helicobacter pylori eradication therapy in relation to changes in the intestinal microbiota

Microbiology and Immunology - Tập 52 Số 3 - Trang 156-161 - 2008
Kyoto Imase1, Motomichi Takahashi2,3, Akifumi Tanaka1, K. Tokunaga1, Hajime Sugano1, Mamoru Tanaka3, Hitoshi Ishida1, Shigeru Kamiya2, Shinʼichi Takahashi1
1Third Department of Internal Medicine
2Department of Infectious Disease, Kyorin University School of Medicine, 6-20-2, Shinkawa, Mitaka, Tokyo, Japan
3Miyarisan Pharmaceutical, 1-10-3, Kaminakazato, Kita-ku, Tokyo, Japan

Tóm tắt

ABSTRACT

Antibiotic associated diarrhea due to human intestinal microbiota abnormalities is a side effect of H. pylori eradication therapy. We examined intestinal microbiota changes during H. pylori eradication therapy and the preventive effect of CBM588 as a probiotic agent. Nineteen patients with gastro‐duodenal ulcer were randomly divided into three groups: group A (without probiotics), group B (with regular doses of CBM588) and group C (with double doses of CBM588). The incidence of diarrhea and soft stools during H. pylori eradication therapy was 43% in group A and 14% in group B, while none of the patients in group C reported diarrhea or soft stools. Both bacterial counts and detection rates of bifidobacteria and/or obligate anaerobe were decreased by eradication therapy. However, bacterial counts of obligate anaerobes in group C were significantly higher than in group A (P < 0.05). Additionally, during eradication therapy C. difficile toxin A was detected in both group A and group B but not in group C.

In conclusion, these results indicate that H. pylori eradication therapy induces antibiotic associated diarrhea due to abnormalities in intestinal microbiota and/or C. difficile. However, these side effects might be prevented by probiotics.

Từ khóa


Tài liệu tham khảo

10.1136/gut.41.1.8

10.1111/j.1574-6976.2005.00006.x

10.1046/j.1523-5378.2001.00037.x

10.1046/j.1365-2036.1999.00526.x

10.1136/bmj.324.7350.1361

10.1111/j.1572-0241.2006.00465.x

10.1046/j.1442-200X.2003.01671.x

10.1111/j.1348-0421.1997.tb01909.x

Mitsuoka T., 2002, Research in intestinal flora and functional foods, J Intestinal Microbiol, 15, 57

10.1128/JCM.39.8.2846-2849.2001

Ables A., Z., 2007, Update on Helicobacter pylori treatment, Am Fam Physician, 75, 351

10.1056/NEJMcp011603

10.1046/j.1365-2036.2001.01033.x

Pothoulakis C., 1993, Clostridium difficile colitis and diarrhea, Gastroenterol Clin North Am, 22, 623, 10.1016/S0889-8553(21)00093-5

10.1097/00013542-199712001-00029

10.1099/0022-1317-49-7-635

10.1016/j.femsim.2004.03.010

10.1023/A:1026647024077

10.1007/s005350050358

10.1007/BF01312224

Nakaya R., 1985, Antibiotics and intestinal bacterial flora, Biomedicine Ther, 14, 598

Ducluzeau R., 1977, Antagonistic effect of extremely oxygen sensitive clostridia from the microflora of conventional mice and of Escherichia coli against Shigella flexneri in the digestive tract of gnotobiotic mice, Infect Immun, 17, 415, 10.1128/iai.17.2.415-424.1977

10.1093/clinids/16.Supplement_2.S77

10.1016/0016-5085(91)90384-W

Tanaka M., 2000, Preventive effect of Clostridium butyricum on the side effect of the Helicobacter pylori eradication, Chin J Gastroenterol, 5, A116

10.1056/NEJM198901263200402

Oldfield E.C., 2004, Clostridium difficile‐associated diarrhea: risk factors, diagnostic methods, and treatment, Rev Gastroenterol Disord, 4, 186

10.1046/j.1365-2036.1996.79251000.x

10.1111/j.1572-0241.1998.00358.x

10.11150/kansenshogakuzasshi1970.64.257

10.1016/j.femsre.2004.01.003

10.1016/S1473-3099(06)70627-2

Thông tin
Thông tin xuất bản

Microbiology and Immunology

Tập 52 Số 3

156-161

Thông tin tác giả